MEPOLIZUMAB
215360
Phase 3 small_molecule active
Quick answer
MEPOLIZUMAB for Hypereosinophilic syndrome (HES) is a Phase 3 program (small_molecule) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline Biologicals S.A.
- Indication
- Hypereosinophilic syndrome (HES)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active